Type 2 Diabetes Trial, Recruiting (NCT07023172)

Type 2 Diabetes Trial, Recruiting NCT07023172 Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT07023172 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years old or older, of any gender
You have been diagnosed with type 2 diabetes according to standard Chinese medical guidelines
Your doctor has decided that a diabetes medication called proline-containing gliflozin tablets (brand name: Hui You Jing) is right for you, and you have never taken this specific medication before
You have had a blood sugar control test (called an HbA1c test) done within the last 4 weeks
You are willing to take part and have signed a consent form agreeing to join the study

Who may not be able to join:

You have moderate to severe kidney disease, kidney failure, or are currently on dialysis (confirm with trial site)
You have a condition where your blood becomes too acidic, including a serious diabetes-related complication called diabetic ketoacidosis
You have a severe allergy to gliflozin or any ingredient in the study medication
You are currently taking part in, or have taken part in, another clinical trial within the last month
The trial doctor does not think the study is a good fit for you for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 86+13655176388

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07023172

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: 86+13655176388

More information: https://clinicaltrials.gov/study/NCT07023172

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years old or older, of any gender
You have been diagnosed with type 2 diabetes according to standard Chinese medical guidelines
Your doctor has decided that a diabetes medication called proline-containing gliflozin tablets (brand name: Hui You Jing) is right for you, and you have never taken this specific medication before
You have had a blood sugar control test (called an HbA1c test) done within the last 4 weeks
You are willing to take part and have signed a consent form agreeing to join the study

Who may not be able to join:

You have moderate to severe kidney disease, kidney failure, or are currently on dialysis (confirm with trial site)
You have a condition where your blood becomes too acidic, including a serious diabetes-related complication called diabetic ketoacidosis
You have a severe allergy to gliflozin or any ingredient in the study medication
You are currently taking part in, or have taken part in, another clinical trial within the last month
The trial doctor does not think the study is a good fit for you for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Registry

ClinicalTrials.gov

Start date

30 May 2025

Est. completion

1 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

HbA1c <7.0%

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov